Cost–utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B
<p><strong>Objective</strong></p> <p>The aim of this study was to assess the cost-effectiveness of tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis B (CHB) versus alternative nucleos(t)ides from a UK National Health Service (NHS) perspective.<...
Main Authors: | Dakin, H, Bentley, A, Dusheiko, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Elsevier
2011
|
Similar Items
-
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
by: Dakin, H, et al.
Published: (2011) -
Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective.
by: Dakin, H, et al.
Published: (2011) -
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01) -
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection
by: J Jones, et al.
Published: (2010-05-01) -
Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
by: Yim HJ, et al.
Published: (2022-09-01)